Skip Section Navigation

Institutional Biosafety Review

Certain types of research—particularly those involving genetically modified organisms, infectious agents, or specific biological materials—can pose potential risks to researchers, the public, and the environment. To safeguard health and ensure regulatory compliance, such projects often require oversight by the Institutional Biosafety Committee (IBC).

The IBC, mandated by the National Institutes of Health, is responsible for reviewing all research involving recombinant or synthetic nucleic acid molecules. Its role is to assess whether work with biohazardous materials is being conducted in a safe, ethical, and responsible manner. This review process is essential for protecting all stakeholders and ensuring adherence to federal regulations and best practices. If your research may involve biological risks, the Institutional Biosafety Review team is ready to guide and support you throughout the process.

The UNT IBC currently oversees:

  • Recombinant DNA and synthetic nucleic acid molecules
  • Infectious agents (bacteria, fungi, protozoa, parasites, viruses, prions, etc.)
  • All human and non-human primate-derived materials
  • Transgenic animals, invertebrates, and/or plants
  • All animal-derived materials
  • Field studies involving biological sample collection or live animal handling
  • Toxins of Biological Origin
  • Federally Regulated Select Agents
  • Dual Use Research of Concern potential
  • Gene transfer or therapy
  • Synthetic biology
  • International, Federal, and State Transport Regulations

*This list is not exhaustive. For a complete list of research materials that fall under the purview of IBC, please contact the Biosafety Officer or the IBC Chair.
The IRB and IACUC do not consider biosafety issues during their respective reviews. They rely on the Institutional Biosafety Committee to perform this aspect of the review.

Contact:

Contact the IBC at: IBCprogram@unt.edu

Biosafety Officer: Dr. Veena Naik: veena.naik@unt.edu